Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses the goals she would like to see achieved regarding the treatment of ovarian cancer.
Jasgit Sachdev, MD
Advertisement
Articles by Jasgit Sachdev, MD
Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Jasgit Sachdev on Antibody-Drug Conjugate PF-06647020 in Ovarian CancerPublished: October 18th 2016 | Updated:
Dr. Jasgit Sachdev on What's on the Horizon for Ovarian CancerPublished: November 23rd 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5